Prognostic importance of cyclin E1 expression in neuroblastic tumors in children

Polish Journal of Pathology

Volumn 64, Issue 2, 2013, Pages 149-152

  Taran, Katarzyna ^a   Owecka, Agata ^a   Kobos, Józef ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Childhood; Cyclin E; Neuroblastoma; Prognosis

Indexed keywords

CCNE1 PROTEIN, HUMAN; CYCLIN E; ONCOPROTEIN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; CHILD; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; METABOLISM; MORTALITY; NEUROBLASTOMA; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS;

CHILD; CHILD, PRESCHOOL; CYCLIN E; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; ONCOGENE PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880296245     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2013.36016     Document Type: Article

References (22)

1. Schor N. Neuroblastoma. Drug Discovery Today: Disease Mod-els 2006; 3: 387-390.
2. Stefanowicz J, Izycka-Świeszewska E, Drozyńska E, et al. Neuroblastoma and opsoclonus-myoclonus-ataxia syndrome - clinical and pathological characteristics. Folia Neuropathol 2008; 46: 176-185.
3. Izycka-Świeszewska E, Brzeskwiniewicz M, Woźniak A, et al. EGFR, PIK3CA and PTEN gene status and their protein prod-uct expression in neuroblastic tumours. Folia Neuropathol 2010; 48: 238-245.
4. Hildebrandt T, Traunecker H. Neuroblastoma: A tumor with many faces. Current Paediatrics 2005; 15: 412-420.
5. Tononi G.P, Romani M. Genetic and epigenetic alterations in neuroblastoma. Cancer Lett 2003; 197: 69-73.
6. Noesel MM, Versteeg R: Pediatric neuroblastomas: genetic and epigenetic "Dance Macabre". Gene 2004; 325: 1-15.
7. Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 2005; 228: 133-141.
8. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120.
9. Tonini GP, Longo L, Coco S, Perri P. Familial neuroblastoma: a complex heritable disease. Cancer Lett 2003; 197: 41-45.
10. Ross RA, Biedler JL, Spengler BA: A role for distinct cell types in determining malignancy in human neuroblastoma lines and tumors. Cancer Lett 2003; 197: 35-39.
11. Chlenski A, Liu S, Cohn SL. The regulation of angiogenesis in neuroblastoma. Cancer Lett 2003; 197: 47-52.
12. Möröy T, Geisen C. Cyclin E. Int J Biochem Cell Biol 2004; 36: 1424-1439.
13. Geng Y, Lee YM, Welcker M, et al. Kinase-independent func-tion of cyclin E. Mol Cell 2007; 25: 127-139.
14. Zhang H: Life without Kinase: Cyclin E Promotes DNA Repli-cation Licensing and Beyond. Molecular Cell 2007; 25: 175-176.
15. Payton M, Coats S: Cyclin E2, the cycle continues. Int J Biochem Cell Biol 2002; 34: 315-320.
16. Roberts JM, Sherr CJ. Bared essentials of CDK2 and cyclin E. Nat Genet 2003; 35: 9-10.
17. Coqueret O. Linking cyclins to transcriptional control. Gene 2002; 299: 35-55.
18. Loeb KR, Kostner H, Firpo E, et al. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 2005; 8: 35-47.
19. Molenaar JJ, Ebus ME, Koster J, et al. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neu-roblastoma. Cancer Res 2008; 68: 2599-2609.
20. Berrebi D, Leclerc J, Schleiermacher G, et al. High cyclin E stain-ing index in blastemal, stromal or epithelial cells is correlated with tumor aggressiveness in patients with nephroblastoma. Plos One 2008; 3: 1-9.
21. Sałacińska-Łoś E, Kobos J, Taran K. Estimation of diagnostic value of chosen markers of neural differentiation in neuroblas-toma group of tumors and pPNETs. Pol J Pathol 2008, 59: 195-199.
22. Taran K, Kobos J, Sitkiewicz A, Sporny S. Estimation of prog-nostic value of CD44 expression in neuroblastic tumors in chil-dren. Folia Neuropathologica 2007; 45: 126-132.